11/9 Late treatment study
et al., Intern. Emerg. Med., doi:10.1007/s11739-020-02543-5 (Peer Reviewed)
Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry
Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry
Retrospective database study of 1,021 patients in Ecuador, Germany, Italy, and Spain, showing HCQ propensity score adjusted mortality odds ratio aOR 0.88, p=0.005.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Núñez-Gil et al., 11/9/2020, retrospective, database analysis, multiple countries, Europe, peer-reviewed, median age 68.0, 49 authors.
risk of death, 7.9% lower, RR 0.92, p = 0.005, treatment 200 of 686 (29.2%), control 100 of 268 (37.3%), adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.